← Leaderboards
Miguel Mauricio Cabada
Universidad Peruana Cayetano Heredia
$4,387,032
Attributed
$6,163,732
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,163,732 · 4
By mechanism
U01$3,502,067 · 2
R01$2,661,665 · 2
Top collaborators
- Makedonka Mitreva4 shared
- Hector Hugo Garcia3 shared
Most similar at Universidad Peruana Cayetano Heredia
Same institution · by research overlap
- Hector Hugo Garcia$15,933,000
- Patricia Jannet Garcia$2,913,688
- Joseph Raymond Zunt$11,635,157
- Eduardo Gotuzzo$8,314,389
- Javier A Bustos$2,011,690
Others in their field
Top investigators on “Peru”
- Lawrence Corey · Fred Hutchinson Cancer Center$205,096,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$45,710,868
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Robert M. Grant · J. David Gladstone Institutes$41,279,316
Research focus
PeruFascioliasisChildCountryAffectAreaInfectionFasciolaZoonosesParasitesAnemiaResponseReportingHelminthsFasciola HepaticaPharmaceutical PreparationsResearch PersonnelNeglected Tropical DiseasesEpidemiologyLivestockAnimalsDeveloping CountriesEvaluationCommunities
Grant awards (16)
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis$561,459
U01 · FY2025 · AI
One-Health Approach to Study Human Fasciola hepatica Transmission and Inform Strategic Control$467,735
U01 · FY2025 · AI · contact PI
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis$549,802
U01 · FY2024 · AI
One-Health Approach to Study Human Fasciola hepatica Transmission and Inform Strategic Control$476,993
U01 · FY2024 · AI · contact PI
One-Health Approach to Study Human Fasciola hepatica Transmission and Inform Strategic Control$480,081
U01 · FY2023 · AI · contact PI
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis$439,115
U01 · FY2023 · AI
One-Health Approach to Study Human Fasciola hepatica Transmission and Inform Strategic Control$526,882
U01 · FY2022 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$483,573
R01 · FY2022 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$487,857
R01 · FY2021 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$497,882
R01 · FY2020 · AI · contact PI
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru$533,713
R01 · FY2019 · AI · contact PI
Impact of Fascioliasis among Children in the Peruvian Highlands$131,837
R01 · FY2017 · AI · contact PI
Impact of Fascioliasis among Children in the Peruvian Highlands$131,837
R01 · FY2016 · AI · contact PI
Impact of Fascioliasis among Children in the Peruvian Highlands$131,837
R01 · FY2015 · AI · contact PI
Impact of Fascioliasis among Children in the Peruvian Highlands$131,837
R01 · FY2014 · AI · contact PI
Impact of Fascioliasis among Children in the Peruvian Highlands$131,292
R01 · FY2013 · AI · contact PI